chr8-119732159-C-T
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The NM_003184.4(TAF2):c.3365G>A(p.Ser1122Asn) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0691 in 1,613,680 control chromosomes in the GnomAD database, including 5,010 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★). Another nucleotide change resulting in the same amino acid substitution has been previously reported as Likely benign in UniProt.
Frequency
Consequence
NM_003184.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -20 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TAF2 | ENST00000378164.7 | c.3365G>A | p.Ser1122Asn | missense_variant | 26/26 | 1 | NM_003184.4 | ENSP00000367406.2 | ||
TAF2 | ENST00000686879.1 | c.3521G>A | p.Ser1174Asn | missense_variant | 27/27 | ENSP00000509206.1 | ||||
TAF2 | ENST00000685235.1 | c.3410G>A | p.Ser1137Asn | missense_variant | 26/26 | ENSP00000510174.1 | ||||
TAF2 | ENST00000688645.1 | c.3254G>A | p.Ser1085Asn | missense_variant | 25/25 | ENSP00000509978.1 | ||||
TAF2 | ENST00000523904.2 | c.3251G>A | p.Ser1084Asn | missense_variant | 25/25 | 3 | ENSP00000430832.2 | |||
TAF2 | ENST00000690144 | c.*496G>A | 3_prime_UTR_variant | 26/26 | ENSP00000510548.1 | |||||
TAF2 | ENST00000685202.1 | n.*890G>A | non_coding_transcript_exon_variant | 27/27 | ENSP00000509214.1 | |||||
TAF2 | ENST00000685503.1 | n.*2757G>A | non_coding_transcript_exon_variant | 26/26 | ENSP00000509198.1 | |||||
TAF2 | ENST00000685663.1 | n.*3237G>A | non_coding_transcript_exon_variant | 28/28 | ENSP00000508988.1 | |||||
TAF2 | ENST00000685684.1 | n.*4832G>A | non_coding_transcript_exon_variant | 25/25 | ENSP00000509441.1 | |||||
TAF2 | ENST00000685824.1 | n.*3066G>A | non_coding_transcript_exon_variant | 24/24 | ENSP00000510262.1 | |||||
TAF2 | ENST00000685876.1 | n.*3083G>A | non_coding_transcript_exon_variant | 27/27 | ENSP00000510493.1 | |||||
TAF2 | ENST00000685993.1 | n.*3180G>A | non_coding_transcript_exon_variant | 25/25 | ENSP00000510102.1 | |||||
TAF2 | ENST00000686098.1 | n.*2010G>A | non_coding_transcript_exon_variant | 25/25 | ENSP00000509102.1 | |||||
TAF2 | ENST00000688037.1 | n.*2784G>A | non_coding_transcript_exon_variant | 23/23 | ENSP00000510169.1 | |||||
TAF2 | ENST00000689164.1 | n.*3983G>A | non_coding_transcript_exon_variant | 24/24 | ENSP00000508729.1 | |||||
TAF2 | ENST00000689919.1 | n.*2972G>A | non_coding_transcript_exon_variant | 26/26 | ENSP00000510768.1 | |||||
TAF2 | ENST00000690808.1 | n.*2601G>A | non_coding_transcript_exon_variant | 26/26 | ENSP00000509791.1 | |||||
TAF2 | ENST00000690922.1 | n.*1777G>A | non_coding_transcript_exon_variant | 26/26 | ENSP00000509498.1 | |||||
TAF2 | ENST00000691880.1 | n.*3021G>A | non_coding_transcript_exon_variant | 25/25 | ENSP00000508515.1 | |||||
TAF2 | ENST00000692518.1 | n.*3231G>A | non_coding_transcript_exon_variant | 25/25 | ENSP00000508959.1 | |||||
TAF2 | ENST00000692707.1 | n.*3233G>A | non_coding_transcript_exon_variant | 28/28 | ENSP00000509024.1 | |||||
TAF2 | ENST00000692916.1 | n.*2752G>A | non_coding_transcript_exon_variant | 25/25 | ENSP00000509603.1 | |||||
TAF2 | ENST00000685202.1 | n.*890G>A | 3_prime_UTR_variant | 27/27 | ENSP00000509214.1 | |||||
TAF2 | ENST00000685503.1 | n.*2757G>A | 3_prime_UTR_variant | 26/26 | ENSP00000509198.1 | |||||
TAF2 | ENST00000685663.1 | n.*3237G>A | 3_prime_UTR_variant | 28/28 | ENSP00000508988.1 | |||||
TAF2 | ENST00000685684.1 | n.*4832G>A | 3_prime_UTR_variant | 25/25 | ENSP00000509441.1 | |||||
TAF2 | ENST00000685824.1 | n.*3066G>A | 3_prime_UTR_variant | 24/24 | ENSP00000510262.1 | |||||
TAF2 | ENST00000685876.1 | n.*3083G>A | 3_prime_UTR_variant | 27/27 | ENSP00000510493.1 | |||||
TAF2 | ENST00000685993.1 | n.*3180G>A | 3_prime_UTR_variant | 25/25 | ENSP00000510102.1 | |||||
TAF2 | ENST00000686098.1 | n.*2010G>A | 3_prime_UTR_variant | 25/25 | ENSP00000509102.1 | |||||
TAF2 | ENST00000688037.1 | n.*2784G>A | 3_prime_UTR_variant | 23/23 | ENSP00000510169.1 | |||||
TAF2 | ENST00000689164.1 | n.*3983G>A | 3_prime_UTR_variant | 24/24 | ENSP00000508729.1 | |||||
TAF2 | ENST00000689919.1 | n.*2972G>A | 3_prime_UTR_variant | 26/26 | ENSP00000510768.1 | |||||
TAF2 | ENST00000690808.1 | n.*2601G>A | 3_prime_UTR_variant | 26/26 | ENSP00000509791.1 | |||||
TAF2 | ENST00000690922.1 | n.*1777G>A | 3_prime_UTR_variant | 26/26 | ENSP00000509498.1 | |||||
TAF2 | ENST00000691880.1 | n.*3021G>A | 3_prime_UTR_variant | 25/25 | ENSP00000508515.1 | |||||
TAF2 | ENST00000692518.1 | n.*3231G>A | 3_prime_UTR_variant | 25/25 | ENSP00000508959.1 | |||||
TAF2 | ENST00000692707.1 | n.*3233G>A | 3_prime_UTR_variant | 28/28 | ENSP00000509024.1 | |||||
TAF2 | ENST00000692916.1 | n.*2752G>A | 3_prime_UTR_variant | 25/25 | ENSP00000509603.1 |
Frequencies
GnomAD3 genomes AF: 0.0976 AC: 14838AN: 152078Hom.: 1089 Cov.: 33
GnomAD3 exomes AF: 0.0619 AC: 15569AN: 251316Hom.: 797 AF XY: 0.0590 AC XY: 8007AN XY: 135820
GnomAD4 exome AF: 0.0661 AC: 96625AN: 1461484Hom.: 3921 Cov.: 32 AF XY: 0.0650 AC XY: 47251AN XY: 727076
GnomAD4 genome AF: 0.0976 AC: 14850AN: 152196Hom.: 1089 Cov.: 33 AF XY: 0.0943 AC XY: 7021AN XY: 74422
ClinVar
Submissions by phenotype
not provided Benign:2
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 25, 2024 | - - |
TAF2-related disorder Benign:1
Benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Nov 20, 2019 | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at